In East Asia, approximately half of lung adenocarcinoma (ADC) patients have epidermal growth factor receptor (EGFR) mutations, and tyrosine kinase inhibitor (TKI) therapy is the standard treatment for advanced EGFR-mutant lung ADC [2]. Here, EGFR is linked to lung adenocarcinoma.